

# COLISTIN

Belongs to the polymyxin class of antibiotics. They bind to the lipopolysaccharide molecules in the outer membrane of Gram-negative bacteria leading to disruption of outer membrane stability, leakage and bacterial lysis.


## ANTIMICROBIAL SPECTRUM

- Primarily used in the treatment of nosocomial infections with extensively drug-resistant (XDR) pathogens, such as carbapenem-resistant *Enterobacterales* (*Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter* spp.), *Pseudomonas aeruginosa* and *Acinetobacter baumannii*.
- Moderate activity against *Stenotrophomonas maltophilia*.
- No activity against all Gram-positive organisms, anaerobes and Gram-negative cocci.
- Among Gram-negative, *Proteus* spp., *Providencia* spp., *Burkholderia cepacia*, *Morganella* spp. and *Serratia* spp. are intrinsically resistant to colistin.

### ROUTE

Mainly intravenous, rarely inhalation or intraventricular


## MAIN INDICATIONS



- XDR Gram-negative bacilli hospital-acquired pneumonia, bacteraemia and sepsis.
- Complicated urinary tract infections.
- Adjunctive inhalation therapy for pneumonia caused by XDR Gram-negative bacilli (controversial).
- Warning:** Distribution of IV colistin is poor to the lung parenchyma, pleura, cerebrospinal fluid and bones.

## ADULT DOSE

### Intravenous



- 1,000,000 units = 80 mg colistimethate sodium (CMS) = 30 mg colistin base activity (CBA).
- 1 mg CBA = 2.7 mg CMS = 30,000 units.
- A loading dose of 9 million international units (IU) CMS is warranted, followed 12 hours later by 9 million IU CMS (equivalent to approximately 300 mg CBA) per day in two or three divided doses for patients with normal renal function.
- Use of ideal rather than actual body weight is associated with a lower risk of adverse effects.

### Dosing in patients with renal impairment

A loading dose of 300 mg CBA should be administered followed by a maintenance dose based on CrCl, in 2 or 3 divided doses:

- CrCl 30 to <50 mL/min: 183 to 250 mg CBA/day
- CrCl 10 to <30 mL/min: 150 to 183 mg CBA/day
- CrCl <10 mL/min: 117 mg CBA/day

### Intermittent haemodialysis (IHD)

- On the assumption of 3 times/week, complete IHD sessions.
- Administer after haemodialysis on dialysis days.
- IV Loading dose 300 mg CBA followed by 130 mg CBA once daily. On dialysis days, a supplemental dose of 40 mg CBA or 50 mg CBA for a 3- or 4-hour IHD session, respectively, should be added to the daily maintenance dose.

### Intrathecal / intraventricular

- Intraventricular colistin is administered through intraventricular catheter, as an adjunct to systemic antibiotic therapy.
- Given in a dose of 10 mg CMS (equivalent to 125,000 IU CMS or 4.2 mg CBA) per day in one daily dose or two divided doses every 12 hours.

## SIDE EFFECTS



! Reversible nephrotoxicity (20-60%), haematuria, proteinuria, oliguria and acute renal failure due to acute tubular necrosis.

! Neurotoxicity (7%) includes reversible dizziness, vertigo, ataxia, facial paraesthesia and vertigo.

! Aerosolisation of polymyxins into the airway can be complicated by bronchospasm; bronchodilatation prior to administration may be beneficial.

! Skin hyperpigmentation.

## MONITORING

- Renal function should be closely monitored during administration of colistin. If the patient has a decrease in creatinine clearance while on colistin, the dose should be reduced accordingly.
- Avoid other nephrotoxic agents if possible, and daily monitor renal function any time nephrotoxic combinations are necessary (e.g. vancomycin, aminoglycosides).



### PREGNANCY

FDA Category

C

It should be given only if the potential benefits outweigh the potential risk to the foetus.

## Legal Disclaimer

The information (including but not limited to text, graphics, images and other materials) contained in this document are for informational purposes only. No material contained herein is intended to be a substitute for professional medical advice, diagnosis, treatment or national / local guidelines. Adherence to the information will not ensure successful treatment in every situation. The ultimate judgment regarding the propriety of any specific therapy must be made by the physician and the patient in light of all the circumstances presented by the individual patient, and the known variability and biological behaviour of the disease.